Skip to content
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Menu
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
Read more about the article Can Psychedelic Drugs Treat Physical Pain?

Can Psychedelic Drugs Treat Physical Pain?

  • Post author:Olly PP
  • Post published:September 30, 2021
  • Post category:Industry News

Continue ReadingCan Psychedelic Drugs Treat Physical Pain?
Read more about the article Ecstasy, LSD and magic mushrooms: are these drugs the future of therapy?

Ecstasy, LSD and magic mushrooms: are these drugs the future of therapy?

  • Post author:Olly PP
  • Post published:September 13, 2021
  • Post category:Industry News

Continue ReadingEcstasy, LSD and magic mushrooms: are these drugs the future of therapy?
Read more about the article Psychedelic Drugs Market Global Industry Analysis (2018 – 2020)

Psychedelic Drugs Market Global Industry Analysis (2018 – 2020)

  • Post author:Olly PP
  • Post published:August 30, 2021
  • Post category:Industry News

Continue ReadingPsychedelic Drugs Market Global Industry Analysis (2018 – 2020)
Read more about the article Op-Ed: Psychedelic treatments are here, but doctors aren’t prepared

Op-Ed: Psychedelic treatments are here, but doctors aren’t prepared

  • Post author:Olly PP
  • Post published:August 29, 2021
  • Post category:Industry News

Continue ReadingOp-Ed: Psychedelic treatments are here, but doctors aren’t prepared
Read more about the article Study finds psilocybin repairs brain cell damage associated with depression

Study finds psilocybin repairs brain cell damage associated with depression

  • Post author:Olly PP
  • Post published:July 21, 2021
  • Post category:Industry News

Continue ReadingStudy finds psilocybin repairs brain cell damage associated with depression
Read more about the article Albert Labs announces C$4M financing ahead of CSE listing

Albert Labs announces C$4M financing ahead of CSE listing

  • Post author:Olly PP
  • Post published:April 15, 2021
  • Post category:News

Continue ReadingAlbert Labs announces C$4M financing ahead of CSE listing
Read more about the article Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

  • Post author:Olly PP
  • Post published:December 30, 2016
  • Post category:Industry News

Continue ReadingPsilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Read more about the article Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

  • Post author:Olly PP
  • Post published:December 30, 2016
  • Post category:Industry News

Continue ReadingRapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
  • Go to the previous page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9

Recent Posts

  • Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors
  • Albert Labs Management and Board of Director Announcement
  • Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology
  • Expansion of Drug Discovery and a Promising Pipeline
  • Albert Labs Announces Private Placement

Recent Comments

  • Randal Elliott on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Nicholas Stewart on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Camille Ortega on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Kelly Lambert on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker
  • Dean Phillips on Another Psychedelics Company Goes Public: Albert Labs To List On CSE, Appoints Chrystal Capital As UK Banker

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2024 Albert Labs. All Rights Reserved

  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
  • About
  • Clinical Trials
  • Training
  • KRN-101
  • Investing
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact [email protected]

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

  • This field is for validation purposes and should be left unchanged.
Twitter
Youtube
Linkedin
Instagram
Envelope
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Welcomes Dr. Shabir Hasham to Board of Directors

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.